Labcorp Holdings Inc. has announced plans to offer the Elecsys pTau181 test, the first blood test cleared by the U.S. Food and Drug Administration (FDA) to help rule out Alzheimer's-related amyloid pathology in primary care settings. Developed by Roche Diagnostics, this FDA-cleared test will be made available nationwide by Labcorp by early 2026. The test, performed via a simple blood draw, provides a less invasive and more accessible alternative to traditional diagnostic methods such as lumbar punctures and PET scans for Alzheimer's disease and other causes of cognitive decline.